Giovanna Finocchiaro

AI-HOPE lung cancer: a multicenter real-world registry integrating artificial intelligence for metastatic non-small-cell lung cancer

Francesca Rita Ogliari, M. Ferrara, Jarno W J Huijs, A. Traverso et autres

Background The AI-HOPE Lung Cancer study is a multicenter initiative designed to integrate artificial intelligence (AI) and real-world data to improve outcome prediction in patients with metastatic non-small-cell lung cancer treated with first-line immunotherapy-based regimens. AI-HOPE aims to leverage machine learning (ML) …

it, nl, at, pt (code pays fourni par la source)

Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)–based combination therapy for non–small cell lung cancer (NSCLC).

Martin Gutierrez, Wei‐Sen Lam, Adam J. Schoenfeld, Matthew A. Gubens et autres

8584 Background: KEYNOTE-495/KeyImPaCT (NCT03516981) evaluated 3 P-based regimens in participants (pts) with advanced NSCLC across 4 prospectively defined biomarker subgroups based on T-cell–inflamed gene expression profile (Tcell inf GEP) and tumor mutational burden (TMB). In interim analysis, ORR with P + lenvatinib …

us, au, sg, es, cn, hk, kr, tw, it (code pays fourni par la source)

Circulating tumor DNA (ctDNA) in early-stage NSCLC: a new frontier in precision oncology

Silvia Masini, Matteo Fila, Angelica Michelini, Michele Vinciguerra et autres

Recent advances in the management of early-stage non-small cell lung cancer (NSCLC), including perioperative immunotherapy and targeted treatments, have significantly improved outcomes. Nevertheless, a considerable proportion of patients relapse after curative-intent surgery, emphasizing the need for biomarkers that can more accurately define …

it (code pays fourni par la source)

PIK3CA Alterations in NSCLC: Clinical Characteristics of a “Neglected” Population of Oncogene-Addicted Patients

Sabrina Rossi, Arianna Pagliaro, Silvia Masini, Giovanna Finocchiaro et autres

Background/Objectives: Alterations of the phosphatidylinositol 3-kinase catalytic subunit alpha gene (PIK3CA) are identified in approximately 2–4% of non-small cell lung cancer (NSCLC) cases; however, their biological and clinical relevance in NSCLC remains incompletely understood. This study aimed to comprehensively characterize the clinical …

it (code pays fourni par la source)

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial

Chiara Mattioli, Emanuela Olmetto, Saverio Caini, Marco Del Riccio et autres

BACKGROUND: Very little is known regarding the clinical value of inflammatory blood markers, such as NLR, Systemic Immune Inflammation (SII), derived NLR (dNLR) and Lung Immune Prognostic Index (LIPI) in stage III NSCLC patients treated as per PACIFIC regimen. METHODS: Neutrality trial …

it, us (code pays fourni par la source)

Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study

Paolo Bironzo, Alessandro Morabito, Sonia Silipigni, Vincenzo Adamo et autres

BACKGROUND: Stage III non-small cell lung cancer (NSCLC) includes a heterogeneous group of patients with diverse disease presentation, biological portrait, and prognosis. Optimal management requires tailored approaches and multimodal strategies through a multidisciplinary team (MDT) decision-making process. The BE-PACIFIC study primarily aimed …

it, us, gb (code pays fourni par la source)

787 RORγ bridges cancer-driven lipid dysmetabolism and myeloid immunosuppression

Augusto Bleve, Martina Incerti, Francesca Maria Consonni, Valentina Garlatti et autres

Background Cancer-related inflammation promotes the expansion of immunosuppressive myeloid cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which support tumor progression and immune evasion. These alterations are often associated with lipid and cholesterol dysregulations. However, the mechanistic links between …

us, it (code pays fourni par la source)

P1.11.01 First-Line Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metastatic NSCLC: Real World Data in Italy

F. Agustoni, G Gambini, G. Lo Russo, C. Proto et autres

it, ca, us (code pays fourni par la source)

1809eP Eligibility for adjuvant chemotherapy in patients with surgically resected non-small cell lung cancer: Implications for the use of adjuvant immune checkpoint inhibitors

S. Masini, Marc Fila, Manlio Vinciguerra, Giovanna Finocchiaro et autres

it (code pays fourni par la source)

Figure S10 from RORγ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression

Augusto Bleve, Martina Incerti, Francesca Maria Consonni, Valentina Garlatti et autres

Blockade of cholesterol-RORγ axis restrains tumor progression and myeloid cell immunosuppressive functions

Figure S8 from RORγ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression

Augusto Bleve, Martina Incerti, Francesca Maria Consonni, Valentina Garlatti et autres

Myeloid-specific genetic deletion of RORγ regulates tumor-promoting immunosuppressive myelopoiesis

Figure S3 from RORγ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression

Augusto Bleve, Martina Incerti, Francesca Maria Consonni, Valentina Garlatti et autres

Cholesterol levels modulate cancer-driven myeloid immunosuppression